Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention

Authors:
  • DWD. Lawrence Wickerham
    D. Lawrence Wickerham
  • JCJoseph P. Costantino
    Joseph P. Costantino
  • MRMarcie W. Ritter
    Marcie W. Ritter
  • VVVictor G. Vogel
    Victor G. Vogel
  • MLMyoungkeun Lee
    Myoungkeun Lee
  • EPEduardo R. Pajon
    Eduardo R. Pajon
  • JWJames L. Wade
    James L. Wade
  • SDShaker Dakhil
    Shaker Dakhil
  • JLJames B. Lockhart
    James B. Lockhart
  • NWNorman Wolmark
    Norman Wolmark
  • PGPatricia A. Ganz
    Patricia A. Ganz

Abstract
The National Surgical Adjuvant Breast and Bowel Project (NSABP) Study of Tamoxifen and Raloxifene (STAR) was a multicenter, double-blind, randomized phase 3 prevention trial designed to evaluate the relative efficacy of raloxifene (60 mg/d for 5 years) compared with tamoxifen (20 mg/d for 5 years) in reducing the incidence of invasive breast cancer in high-risk postmenopausal women. In addition, it was hypothesized that raloxifene would have a better safety profile with respect to uterine cancer and a number of patient-reported symptoms and would provide a potential alternative to tamoxifen in the prevention of breast cancer in postmenopausal women. Therefore, measurement of patient-reported outcomes was an important secondary objective of the STAR trial.

This publication has 17 references indexed in Scilit: